Zoetis Inc. (ZTS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Zoetis reported revenue of $9.47B, up 2.3% from $9.26B the year before. Net income was $2.67B (a 28.2% net margin), or $6.02 per diluted share. Gross margin was 71.8% and operating margin was 46.7%. Operating activities generated $2.90B of cash, leaving $2.28B of free cash flow. At fiscal year end, Zoetis held $15.47B in total assets against $12.14B in total liabilities.
Open the full interactive Zoetis financials → Quarterly statements, key ratios, valuation history and price charts.
Zoetis Key Stats
| Share Price | $74.30 |
|---|---|
| Market Cap | $31.04B |
| P/E Ratio | 12.3 |
| Revenue YoY Growth | +2.3% |
| 52-Week Range | $69.10 – $144.75 |
| Shares Outstanding | 417.6 million (basic, 2026 Q2) |
Zoetis Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.67B | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B |
| Cost of Goods Sold | $2.06B | $2.30B | $2.45B | $2.56B | $2.72B | $2.67B |
| Gross Profit | $4.62B | $5.47B | $5.63B | $5.98B | $6.54B | $6.80B |
| Operating Income | $2.89B | $3.47B | $3.62B | $3.83B | $4.22B | $4.42B |
| Pre-Tax Income | $2.00B | $2.49B | $2.66B | $2.94B | $3.13B | $3.36B |
| Income Tax | $360.0M | $454.0M | $545.0M | $596.0M | $637.0M | $687.0M |
| Net Income | $1.64B | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B |
| Diluted EPS | $3.42 | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
Zoetis Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $2.40B | $2.39B | $2.26B | $2.47B |
| Net Income | $721.0M | $603.0M | $601.0M | $691.0M |
| Diluted EPS | $1.63 | $1.36 | $1.42 | $1.65 |
Zoetis Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Current Assets | $6.61B | $6.93B | $7.51B | $6.34B | $5.99B | $6.77B |
| Total Assets | $13.61B | $13.90B | $14.93B | $14.29B | $14.24B | $15.47B |
| Current Liabilities | $2.17B | $1.80B | $3.17B | $1.89B | $3.41B | $2.23B |
| Total Long-Term Debt | $7.20B | $6.59B | $7.90B | $6.56B | $6.57B | $9.04B |
| Total Liabilities | $9.84B | $9.36B | $10.52B | $9.29B | $9.47B | $12.14B |
| Shareholders' Equity | $3.77B | $4.54B | $4.41B | $5.00B | $4.77B | $3.33B |
Zoetis Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $2.13B | $2.21B | $1.91B | $2.35B | $2.95B | $2.90B |
| Cash From Investing | -$572.0M | -$458.0M | -$883.0M | -$777.0M | -$315.0M | -$748.0M |
| Cash From Financing | $123.0M | -$1.86B | -$904.0M | -$3.11B | -$2.66B | -$1.87B |
| Free Cash Flow | $1.67B | $1.74B | $1.33B | $1.62B | $2.30B | $2.28B |
Figures from Zoetis' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Zoetis financials page for every line item.
Zoetis Company Profile
| Ticker | ZTS |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Parsippany, New Jersey |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001555280 |
Frequently Asked Questions
What was Zoetis' revenue in fiscal 2025?
Zoetis (ZTS) reported revenue of $9.47B for fiscal 2025.
What is Zoetis' annual revenue history?
Zoetis' annual revenue by fiscal year: 2020: $6.67B; 2021: $7.78B; 2022: $8.08B; 2023: $8.54B; 2024: $9.26B; 2025: $9.47B.
What was Zoetis' net income in fiscal 2025?
Zoetis reported net income of $2.67B for fiscal 2025.
What was Zoetis' earnings per share (EPS) in fiscal 2025?
Zoetis' diluted EPS was $6.02 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Zoetis generate in fiscal 2025?
Zoetis generated $2.28B of free cash flow in fiscal 2025.
What was Zoetis' revenue last quarter?
In its most recent reported quarter (2026 Q2), Zoetis reported revenue of $2.47B.
How much debt does Zoetis have?
Zoetis reported $9.04B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Zoetis are outstanding?
Zoetis reported a weighted average of 417.6 million basic shares outstanding in 2026 Q2.
What is Zoetis' market cap?
Based on its latest closing price, Zoetis (ZTS) has a market capitalization of about $31.04B.
When does Zoetis' fiscal year end?
Zoetis' fiscal year end, as registered with the SEC, is December 31.
Where is Zoetis headquartered?
Zoetis lists its business address in Parsippany, New Jersey in its SEC filings.